MedTrace Logo

Effectiveness of Intensive Smoking Cessation Interventions in Patients With Cancer

NCT04198688 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 77380

Last updated 2023-07-10

No results posted yet for this study

Summary

Smoking accounts for approximately 30% of total cancer deaths each year. Even though former studies show that persons with a cancer diagnosis are less likely to smoke than the general population up to 50% of people who smoke and have lung cancer do not stop smoking after their diagnosis or frequently relapse after smoking cessation. Continued smoking leads to increased all-cause mortality, increased cancer-specific mortality, and decreased quality of life. It is well-known that cancer patients are interested in smoking cessation therefore smoking cessation interventions play an important role in the management of people with cancer.

This study will evaluate the effectiveness of an intensive smoking cessation interventions on cancer patients in real life. The project provides new knowledge about smokers diagnosed with cancer.

Conditions

  • Tobacco Smoking
  • Cancer
  • Tobacco Cessation

Interventions

BEHAVIORAL

Intensive Smoking Cessation Intervention

The intervention comprises 5-6 meetings during six weeks, and can be held in group or as an individual intervention. It is based on counselling and a clearly structured manual-based patient education programme taught by specially trained staff, and contains individual counselling on nicotine replacement therapy or other medical support, according to the level of dependence measured by the Fagerström test score. The first two weeks cover teaching sessions on: ambivalence and motivation, pros and cons of continuous smoking versus cessation, and a quit date is set between the 2. and 3. week. The last 3 sessions cover: risk situations, withdrawal symptoms and medical support for withdrawal symptoms, relapse prevention and how to handle a completely smoke-free life.

Sponsors & Collaborators

  • Rigshospitalet, Denmark

    collaborator OTHER

  • Aarhus University Hospital Skejby

    collaborator OTHER

  • Danish Cancer Society

    collaborator OTHER

  • Bispebjerg Hospital

    lead OTHER

Principal Investigators

  • Mette Rasmussen, PhD · Bispebjerg and Frederiksberg Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-03
Primary Completion
2018-01-04
Completion
2018-01-04

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04198688 on ClinicalTrials.gov